ClinicalTrials.gg
CompletedNCT01779453Updated Mar 29, 2019

A Study of the Safety, Pharmacokinetic Drug Interaction and Efficacy of ETC-1002 and Atorvastatin in Subjects With Hypercholesterolemia

A Phase 2 interventional study of ETC-1002 and Placebo in Hypercholesterolemia, sponsored by Esperion Therapeutics, Inc.. Completed at 3 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-03-29.

Sponsored by Esperion Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies testing bempedoic acid in Hypercholesterolemia — 1 open to participants now, 1 under way, 1 of them phase 3. bempedoic acid · Hypercholesterolemia.

Enrollment
17th of 21
58 · median 126
Started
2012
with 1 other
Phase 2
10 of 21
none open now
Registered
1st of 21
by date
Lead sponsor
15 of 21
Esperion Therapeutics, Inc.

Among the 21 studies testing bempedoic acid in Hypercholesterolemia, this one is the 17th largest by enrollment, is one of 2 that started in 2012, is one of 10 in phase 2, and was the 1st registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 21 studies testing bempedoic acid in Hypercholesterolemia is open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About bempedoic acid

bempedoic acid: first FDA approval 2020 (NEXLETOL), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing bempedoic acid in Hypercholesterolemia, or all of them as a file.
02

Study summary

This study will assess the safety, atorvastatin pharmacokinetics, and LDL-C lowering efficacy of ETC-1002 versus placebo in hypercholesterolemic subjects on background therapy of atorvastatin 10 mg.

03

Conditions studied

  • Hypercholesterolemia

Keywords

  • Atorvastatin
  • Drug-drug interaction
  • Combination therapy
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For subjects on current daily statin therapy - LDL-C 100-220 mg/dL and triglycerides \<350 mg/dL (prior to switching to sponsor -provided atorvastatin 10 mg/day and stopping all other lipid-regulating drugs and supplements) at the S1 Visit,
  • For subjects not on current daily statin therapy - LDL-C ≥ 110 mg/dL and ≤ 220 mg/dL

Exclusion criteria

Exclusion Criteria:

  • Acute significant cardiovascular disease
  • Uncontrolled hypertension
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
58 participants (actual)

Study arms

  • Experimental
    ETC-1002

    ETC-1002 treatment group, oral once daily

    Drug: ETC-1002 · Drug: Atorvastatin

  • Placebo comparator
    Placebo

    Placebo treatment group, oral once daily

    Drug: Placebo · Drug: Atorvastatin

Interventions

  • Week 1-2, 60 mg/day; Week 3-4, 120 mg/day; Week 5-6, 180 mg/day; Week 7-8, 240 mg/day

  • DrugPlacebo

    Placebo once daily for 8 weeks

  • Atorvastatin 10mg once daily for 8 weeks

06

What researchers measure

Primary outcomes

  1. Area under the plasma concentration versus time curve (AUC) of atorvastatin and its active metabolites

    Time frame: 4 and 8 weeks

  2. Peak plasma concentration (Cmax) of atorvastatin and its active metabolites

    Time frame: 4 and 8 weeks

  3. Number of subjects with adverse events, clinical lab abnormalities and other safety findings

    Time frame: 8 weeks

Secondary outcomes

  1. Percent change in LDL-C

    Time frame: 2, 4, 6 and 8 weeks

  2. Percent change in other lipids and cardio-metabolic risk factors

    Time frame: 2, 4, 6 and 8 weeks

Other outcomes

  1. Area under the plasma concentration versus time curve (AUC) and peak plasma concentration (Cmax) of ETC-1002 and its active metabolite

    Time frame: 4 and 8 weeks

07

Study locations

3 sites
  • Indianapolis, Indiana 46260, United States
  • Louisville, Kentucky 40213, United States
  • Richmond, Virginia 23294, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2012, a primary completion of Aug 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2012
First posted
Jan 30, 2013
Start
Dec 2012
Primary completionActual
Aug 2013
CompletionActual
Aug 2013
Results delay requested
Aug 13, 2015
Last update
Mar 29, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01779453
Responsible party
Sponsor
First posted
Jan 30, 2013
Start date
Dec 2012
Primary completion
Aug 2013
Completion
Aug 2013
Last update
Mar 29, 2019

Study contacts

Noah Rosenberg, MD
study director · Esperion Therapeutics, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bempedoic acid · Atorvastatin

Start the discussion